Guardant Health Inc
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tu… Read more
Guardant Health Inc (GH) - Net Assets
Latest net assets as of December 2025: $-99.31 Million USD
Based on the latest financial reports, Guardant Health Inc (GH) has net assets worth $-99.31 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.01 Billion) and total liabilities ($2.11 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-99.31 Million |
| % of Total Assets | -4.93% |
| Annual Growth Rate | N/A |
| 5-Year Change | -115.4% |
| 10-Year Change | N/A |
| Growth Volatility | 139.54 |
Guardant Health Inc - Net Assets Trend (2016–2025)
This chart illustrates how Guardant Health Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Guardant Health Inc (2016–2025)
The table below shows the annual net assets of Guardant Health Inc from 2016 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-99.31 Million | +28.89% |
| 2024-12-31 | $-139.65 Million | -188.00% |
| 2023-12-31 | $158.68 Million | +163.68% |
| 2022-12-31 | $60.18 Million | -90.67% |
| 2021-12-31 | $645.00 Million | -52.42% |
| 2020-12-31 | $1.36 Billion | +59.86% |
| 2019-12-31 | $847.99 Million | +61.54% |
| 2018-12-31 | $524.95 Million | +70.10% |
| 2017-12-31 | $308.61 Million | +287.23% |
| 2016-12-31 | $79.70 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Guardant Health Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 288688700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | % |
| Other Comprehensive Income | $-4.85 Million | % |
| Other Components | $2.90 Billion | % |
| Total Equity | $-99.31 Million | 100.00% |
Guardant Health Inc Competitors by Market Cap
The table below lists competitors of Guardant Health Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Globe Life Inc
NYSE:GL
|
$11.03 Billion |
|
BridgeBio Pharma Inc
NASDAQ:BBIO
|
$11.03 Billion |
|
ABN AMRO Bank N.V
PINK:AAVMY
|
$11.03 Billion |
|
Postal Savings Bank of China Co. Ltd
PINK:PSBKF
|
$11.06 Billion |
|
China Tungsten and Hightech Materials Co Ltd
SHE:000657
|
$11.02 Billion |
|
Guangdong Songfa Ceramics Co
SHG:603268
|
$11.01 Billion |
|
BCEIF
PINK:BCEIF
|
$11.01 Billion |
|
The New York Times Company
F:NYT
|
$11.01 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Guardant Health Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -139,647,000 to -99,307,000, a change of 40,340,000.
- Net loss of 416,277,000 reduced equity.
- Share repurchases of 13,585,000 reduced equity.
- New share issuances of 345,000,000 increased equity.
- Other comprehensive income increased equity by 349,000.
- Other factors increased equity by 124,853,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-416.28 Million | -419.18% |
| Share Repurchases | $13.59 Million | -13.68% |
| Share Issuances | $345.00 Million | +347.41% |
| Other Comprehensive Income | $349.00K | +0.35% |
| Other Changes | $124.85 Million | +125.72% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Guardant Health Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $6.03 | $88.75 | x |
| 2017-12-31 | $4.36 | $88.75 | x |
| 2018-12-31 | $5.68 | $88.75 | x |
| 2019-12-31 | $8.81 | $88.75 | x |
| 2020-12-31 | $13.32 | $88.75 | x |
| 2021-12-31 | $6.37 | $88.75 | x |
| 2022-12-31 | $0.59 | $88.75 | x |
| 2023-12-31 | $1.42 | $88.75 | x |
| 2024-12-31 | $-1.14 | $88.75 | x |
| 2025-12-31 | $-0.79 | $88.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Guardant Health Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -42.39%
- • Asset Turnover: 0.49x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-158.42%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -57.89% | -182.74% | 0.22x | 1.46x | $-54.11 Million |
| 2017 | -26.97% | -166.97% | 0.15x | 1.11x | $-114.08 Million |
| 2018 | -17.61% | -93.85% | 0.15x | 1.22x | $-133.38 Million |
| 2019 | -9.48% | -35.29% | 0.22x | 1.21x | $-155.49 Million |
| 2020 | -19.54% | -88.51% | 0.13x | 1.75x | $-383.63 Million |
| 2021 | -62.89% | -108.57% | 0.17x | 3.42x | $-470.17 Million |
| 2022 | -1087.72% | -145.61% | 0.28x | 26.75x | $-660.61 Million |
| 2023 | -302.14% | -85.02% | 0.32x | 11.26x | $-495.32 Million |
| 2024 | 0.00% | -59.05% | 0.50x | 0.00x | $-422.41 Million |
| 2025 | 0.00% | -42.39% | 0.49x | 0.00x | $-406.35 Million |
Industry Comparison
This section compares Guardant Health Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Guardant Health Inc (GH) | $-99.31 Million | -57.89% | N/A | $11.02 Billion |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |